Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DiCE

Sanofi reception

Leaderless Sanofi sees strong growth

French firm confirms it will seek a new CEO this quarter

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

Sanofi reception

Monthly dosing effective for Sanofi’s alirocumab

New data puts pressure on Amgen's evolocumab

- PMLiVE

France’s taxes make CEO search harder, says Sanofi chairman

Weinberg tells former minister Arnaud Montebourgthat that tax burden is a turn-off for senior executives

Sanofi reception

Sanofi and Evotec discuss high-level outsourcing alliance

Partnership to focus on cancer drug discovery

Sanofi reception

Sanofi’s Priftin cleared for latent tuberculosis in the US

FDA approves Priftin with isoniazid for patients aged two years and older

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

Sanofi reception

Sanofi plans 18 new product launches by 2020

Keen to reinstall faith of investors after firing CEO Viehbacher

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

Sanofi reception

Sanofi persuades FDA to back its MS drug Lemtrada

But only for a limited patient population, with boxed warnings and a risk plan

- PMLiVE

Sanofi board votes out CEO Viehbacher

Unanimous decision ends weeks of speculation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links